Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.0849
Abstract: Key Points Question Is there a difference in outcomes associated with sequential intravesical gemcitabine and docetaxel therapy vs bacillus Calmette-Guérin (BCG) therapy, the standard of care for the treatment of high-risk non–muscle-invasive bladder cancer (NMIBC)?… read more here.
Keywords: gemcitabine docetaxel; high risk; patients high;
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cancer"
DOI: 10.1186/s12885-018-4872-x
Abstract: BackgroundThe combination of gemcitabine and docetaxel (GT) has been demonstrated to be effective against various types of solid tumors, including sarcoma. However, the regimen has not been confirmed in large, well-designed clinical trials in refractory… read more here.
Keywords: gemcitabine docetaxel; metastatic osteosarcoma; combination gemcitabine; refractory metastatic ... See more keywords
The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Management and Research"
DOI: 10.2147/cmar.s378264
Abstract: Purpose The options for the second-line treatment of metastatic osteosarcoma are still limited. Anlotinib is a multi-kinase inhibitor which has shown promising efficacy and good tolerability in various cancer types. This retrospective study was conducted… read more here.
Keywords: gemcitabine docetaxel; combination; group; docetaxel patients ... See more keywords